Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Muscle-invasive and advanced bladder cancer, drawn from the whole corpus: 49 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cisplatin-ineligible patients still have fewer options.
Choosing between cystectomy and bladder preservation lacks randomised evidence.
Variant histologies are excluded from most trials.
Cost and access to antibody-drug conjugates.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
High-risk NMIBC with BCG
EFS HR 0.
A milestone in how this cancer is treated.
OS HR 0.
A milestone in how this cancer is treated.